ClinicalTrials.gg
RecruitingNCT05990153Updated Aug 14, 2023

Evaluation of the Efficacy of Manual Therapy, Therapeutic Exercise and the Two Modalities Combined in Pain Reduction in Patients With Headache

An interventional study of Myofascial Release (MR) and clinical practice drug treatment in Headache, sponsored by Campus Bio-Medico University. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-14.

Sponsored by Campus Bio-Medico University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2025, 1 year 9 months ago, but the record still lists the study as recruiting.
  • Started Apr 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Headache with a site in Italy — 7 open to participants now, 10 under way, 2 of them phase 3. Headache · Italy.

Planned enrollment
15th of 20
100 · median 298
Started
2023
with 5 others
No phase
8 of 32
1 open now
Registered
21st of 32
by date
Lead sponsor
1 of 32
Campus Bio-Medico University

Among the 32 studies in Headache with a site in Italy, this one is the 15th largest by planned enrollment of the 20 interventional ones that give a count, is one of 6 that started in 2023, is one of 8 with no phase, and was the 21st registered.

Headache

764 studies on the registry are indexed under Headache; 134 are open to participants now.

Browse Headache studies →

Open to participants now

7 of the 32 studies in Headache with a site in Italy are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 83 Headache studies recruiting now, 30 (36%) set no upper age limit and 44 (53%) stop at 75 or younger; 10 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Headache with a site in Italy, or all of them as a file.
02

Study summary

The study aims to evaluate which is the best approach for the non-pharmacological treatment of patients with different types of primary headaches (tension-type headache (TTC), trigeminal autonomic headache (TACs) and migraine) or cervicogenic headache by comparing three methods of intervention to control treatment (drug therapy): therapeutic exercise (TE), myofascial release + TE, and Mulligan's manual therapy + TE. The efficacy will be evaluated in terms of reduction of headache episodes, pain intensity and its duration.

Read the detailed description

Patients will be evaluated before the start of treatment (T0), at the end of treatment (T1), 3 months after T1 (T2), 6 months after T1 (T3). Results will be stratified by gender, age range, and type of headache diagnosed.

The 3 non-pharmacological treatment groups will carry out 12 treatment sessions, 3 times a week for 4 weeks, with a duration of 45 minutes each. The control group (CTRL) will carry out pharmacological treatment according to clinical practice, the patients of the CTRL group at the end of the last follow-up evaluation (T3 at 6 months) at their request will be randomized into one of the other three intervention groups.

03

Conditions studied

  • Headache

Keywords

  • headache
  • rehabilitation
  • manual therapy
  • exercise
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients suffering from primary headache or cervicogenic headache;
  • Age > 18 years;
  • signature of the .

Exclusion criteria

Exclusion Criteria:

  • upper cervical spine instability;
  • cervical arterial insufficiency
  • cervical spine fractures
  • pregnancies
  • rheumatoid arthritis
  • severe cognitive impairment
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Myofascial Release (MR) + Therapeutic exercise (TE)

    Patients in the MR+TE group will undergo 12 sessions (3 d/week) of sub-occipital inhibition treatment as a combined muscle and soft tissue inhibition technique. The physiotherapist will apply deep pressure which will be maintained for a total of 10 minutes until the sub-occipital tissues are released. In addition to this technique, the method of pumping and manual treatment (acupressure) of the trigger points on the sub-occipital muscles, on the upper bundles of the trapezius bilaterally, on the sternocleidomastoid bilaterally and on the scalene muscles bilaterally will be applied for a further 10 minutes for a total treatment with myofascial release equal to 20 minutes. At the end of the MR session, the 20-minute TE session will be performed in the same way as described in the TE intervention group.

    Other: Myofascial Release (MR) · Other: Therapeutic exercise (TE)

  • Experimental
    Manual therapy (MT) + Therapeutic exercise (TE)

    The MT+TE intervention group will carry out rehabilitation treatment with a structured protocol based on mobilizations according to the Mulligan method. Treatment according to Mulligan will be carried out at the discretion of the therapist on the basis of daily evaluations of cervical dysfunction and the eventual manifestation of headache. 5 different techniques will be performed on the patient in 12 sessions (3 v/week, for 4 weeks) as described in Satpute, K., Bedekar, N. \& Hall, T. Effectiveness of Mulligan manual therapy over exercise on headache frequency, intensity and disability for patients with migraine, tension-type headache and cervicogenic headache - a protocol of a pragmatic randomized controlled trial. BMC Musculoskelet Disord 22, (2021)..

    Other: Manual therapy (MT) · Other: Therapeutic exercise (TE)

  • Experimental
    Therapeutic exercise (TE)

    Patients in the TE intervention group will be asked to perform 12 sessions (3 day/week) of TE supervised by a physiotherapist. Each session will have a total duration of 40 min divided into 20 min of aerobic exercise and 20 min of TE. Aerobic exercise consists of a total of 20 min of activity on a stationary bike using parameters to increase performance (intensity over 20 min) progressively based on fatigue (Borg scale).The TE consists of warm-up and cool-down exercises for the cervical ROM, associated with stretching exercises of the cervical and scapulothoracic muscles. After the warm-up, muscle strengthening exercises will be performed (isometric, concentric and eccentric contractions of the cervical muscles).

    Other: Therapeutic exercise (TE)

  • Active comparator
    Control

    Patients assigned to the control group will follow the pharmacological treatment according to medical doctor indications (clinical practice).

    Drug: clinical practice drug treatment

Interventions

  • OtherMyofascial Release (MR)

    Myofascial release therapy is a type of gentle, constant massage that releases tightness and pain throughout myofascial tissues.

  • Drugclinical practice drug treatment

    drug treatment according to the medical indications of clinical practice

  • OtherManual therapy (MT)

    The manual therapy consists of the concurrent application of sustained accessory mobilization applied by a therapist and an active physiological movement to end range applied by the patient. Passive end-of-range overpressure, or stretching, is then delivered without pain as a barrier.

    Also known as: Mulligan Concept

  • OtherTherapeutic exercise (TE)

    The ET consists of an initial phase of aerobic exercise (cyclette), subsequently the intervention foresees exercises for the cervical ROM, stretching exercises of the cervical and scapulothoracic muscles and muscle strengthening exercises (isometric, concentric and eccentrics of the cervical musculature).

06

What researchers measure

Primary outcomes

  1. Headache frequency

    number of headache attacks in one month

    Time frame: 4 weeks (end of treatment)

  2. Headache frequency

    number of headache attacks in one month

    Time frame: 3 months after the end of the treatment

  3. Headache frequency

    number of headache attacks in one month

    Time frame: 6 months after the end of the treatment

Secondary outcomes

  1. Headache clinical presentation

    the Visual Analogue Scale corresponds to the visual representation of the amplitude of pain felt by the patient at rest and in movement of the headache symptom. The scale consists in a straight horizontal line of100 mm length. The ends are defined as the extreme limits of the pain, and is orientated from the left (no pain) to the right (worst pain)

    Time frame: 4 weeks (end of treatment)

  2. Headache clinical presentation

    the Visual Analogue Scale corresponds to the visual representation of the amplitude of pain felt by the patient at rest and in movement of the headache symptom. The scale consists in a straight horizontal line of100 mm length. The ends are defined as the extreme limits of the pain, and is orientated from the left (no pain) to the right (worst pain)

    Time frame: 3 months after the end of the treatment

  3. Headache clinical presentation

    the Visual Analogue Scale corresponds to the visual representation of the amplitude of pain felt by the patient at rest and in movement of the headache symptom. The scale consists in a straight horizontal line of100 mm length. The ends are defined as the extreme limits of the pain, and is orientated from the left (no pain) to the right (worst pain)

    Time frame: 6 months after the end of the treatment

  4. Headache related disability

    The headache related disability is assessed through the neck disability index

    Time frame: 4 weeks (end of treatment)

  5. Headache related Disability

    The headache related disability is assessed through the neck disability index

    Time frame: 3 months after the end of the treatment

  6. Headache related Disability

    The headache related disability is assessed through the neck disability index

    Time frame: 6 months after the end of the treatment

  7. Headache related Disability

    The headache related disability is assessed through the migraine disability assessment test.

    Time frame: 4 weeks (end of treatment)

  8. Headache related Disability

    The headache related disability is assessed through the migraine disability assessment test.

    Time frame: 3 months after the end of the treatment;

  9. Headache related Disability

    The headache related disability is assessed through the migraine disability assessment test.

    Time frame: 6 months after the end of the treatment

  10. Perceived Quality of life

    The quality of life is assessed through the Migraine-Specific Quality of Life Questionnaire (MSQ)

    Time frame: 4 weeks (end of treatment)

  11. Perceived Quality of life

    The quality of life is assessed through the Migraine-Specific Quality of Life Questionnaire (MSQ)

    Time frame: 3 months after the end of the treatment

  12. Perceived Quality of life

    The quality of life is assessed through the Migraine-Specific Quality of Life Questionnaire (MSQ)

    Time frame: 6 months after the end of the treatment

  13. Perceived Quality of life

    The quality of life is assessed through the Short Form-36 Health Survey

    Time frame: 4 weeks (end of treatment)

  14. Perceived Quality of life

    The quality of life is assessed through the Short Form-36 Health Survey

    Time frame: 3 months after the end of the treatment

  15. Perceived Quality of life

    The quality of life is assessed through the Short Form-36 Health Survey

    Time frame: 6 months after the end of the treatment

  16. Cervical Range of Motion

    Active cervical range of motion recorded through the dynamo vald system

    Time frame: 4 weeks (end of treatment)

  17. Cervical Range of Motion

    Active cervical range of motion recorded through the dynamo vald system

    Time frame: 3 months after the end of the treatment

  18. Cervical Range of Motion

    Active cervical range of motion recorded through the dynamo vald system

    Time frame: 6 months after the end of the treatment

  19. Cervical muscles Strength

    Peak strength of the neck muscles will be measured with the Dynamo portable dynamometer (VALD Performance, Australia)

    Time frame: 4 weeks (end of treatment)

  20. Cervical muscles Strength

    Peak strength of the neck muscles will be measured with the Dynamo portable dynamometer (VALD Performance, Australia)

    Time frame: 3 months after the end of the treatment

  21. Cervical muscles Strength

    Peak strength of the neck muscles will be measured with the Dynamo portable dynamometer (VALD Performance, Australia)

    Time frame: 6 months after the end of the treatment

  22. Drug intake

    Number of drug intake reported in the headache diary

    Time frame: 4 weeks (end of treatment)

  23. Drug intake

    Number of drug intake reported in the headache diary

    Time frame: 3 months after the end of the treatment

  24. Drug intake

    Number of drug intake reported in the headache diary

    Time frame: 6 months after the end of the treatment

07

Study locations

1 of 1 sites recruiting
  • Rehabilitation Department Fondazione Policlinico Universitario Campus Bio-Medico
    Roma, RM 00128, Italy
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Feb 2025, 22 months after the start.

Of 177 non-industry interventional studies with no phase under Headache, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 39. This study's planned 22 months is above that.

Counting every sponsor, half of 196 studies reached it within 14 months; a quarter within 6 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2023
First posted
Aug 14, 2023
StartActual
Apr 5, 2023
Primary completionEst.
Feb 2025
CompletionEst.
Apr 2026
Last update
Aug 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05990153
Lead sponsor
Campus Bio-Medico University
Responsible party
Silvia Sterzi (Director of Physical Medicine and Rehabilitative Unit, Campus Bio-Medico University) — Principal investigator
First posted
Aug 14, 2023
Start date
Apr 5, 2023
Primary completion
Feb 2025 (estimated)
Completion
Apr 2026 (estimated)
Last update
Aug 14, 2023

Study contacts

Silvia Sterzi, MD
Contact
s.sterzi@policlinicocampus.it
+390622541624
Marco Bravi, PT
Contact
m.bravi@policlinicocampus.it
+393285357278
Silvia Sterzi, MD
principal investigator · Fondazione Policlinico Universitario Campus Bio-Medico

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion